| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | -0.087 | 0.02 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.081 | 0.02 |
| mRNA | Roscovitine | GDSC1000 | pan-cancer | AAC | -0.14 | 0.02 |
| mRNA | triptolide | CTRPv2 | pan-cancer | AAC | -0.084 | 0.02 |
| mRNA | MK-2206 | GDSC1000 | pan-cancer | AAC | 0.091 | 0.02 |
| mRNA | tipifarnib | CTRPv2 | pan-cancer | AAC | -0.073 | 0.02 |
| mRNA | LY317615 | GDSC1000 | pan-cancer | AAC | 0.083 | 0.02 |
| mRNA | FMK | GDSC1000 | pan-cancer | AAC | 0.09 | 0.02 |
| mRNA | GDC-0449 | GDSC1000 | pan-cancer | AAC | -0.087 | 0.02 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.078 | 0.02 |